Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced NSCLC Patients With T790M × aflutinib × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 10 NSCLC 4 Meningeal Carcinomatosis 2 Lung Neoplasms 2 Brain Neoplasms 2 Respiratory Tract Neoplasms 1 Non Small Cell Lung Cancer NSCLC 1 Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer 1 Bronchial Neoplasms 1 Advanced NSCLC Patients With T790M 1 Advanced NSCLC 1 Advanced Lung Cancer 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03452592 2025-04-03

Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M

Allist Pharmaceuticals, Inc.

Phase 2 Terminated

Advanced NSCLC Patients With T790M

Data powered by HemOnc (CC BY 4.0) Colophon ⚡